Therapeutic Research

Abstract

The efficacy of the combination therapy with ibandronate and eldecalcitol was compared and determined in 190 osteoporotic patients using an endpoint of tartrate –resistant acid phosphatase –5b（TRACP–5b） level, and its safety was also determined. While it was conducted by dividing the patients into an introduction group who newly started a treatment for osteoporosis and a switch group from other drugs, a significant decrease of TRACP–5b level was observed in both groups（p＜0.001）. In addition, in a comparison between a within – reference –standard group and a beyond –reference – standard group, who showed lower and higher TRACP–5b level than the reference standard at baseline, respectively, the TRACP –5b change rate was greater in the beyond–reference–standard group; thus, the greater bone metabolism suppression was observed in patients with more increased bone metabolism.